
Insights Into Acute Myeloid Leukemia (AML) 2021
Perspectives of community physicians on the treatment of acute myeloid leukemia (AML) , recently introduced and upcoming agents
Faculty Chair
Gabriel Mannis, MD
Stanford Health Care, Stanford, CA
More information
- Virtual Series
- Arkansas, Kansas, Louisiana, Missouri, Oklahoma, Texas
More Information
- Virtual Series
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
REPORT SNAPSHOT
- A virtual, moderated roundtable discussion focusing on the treatment of acute myeloid leukemia
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following AML therapies were obtained: venetoclax, gilteritinib, CC-486, azacitidine, cytarabine and daunorubicin (ie, 7+3), CPX-351, ivosidenib, gemtuzumab ozogamicin, midostaurin, and sorafenib
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors will comprise 10–15 medical oncologists representative of each region